Formycon AG (ETR:FYB)
23.25
+0.10 (0.43%)
May 5, 2025, 5:35 PM CET
Formycon AG Revenue
In the year 2024, Formycon AG had annual revenue of 69.67M EUR, down -10.32%. Formycon AG had revenue of 42.78M in the half year ending December 31, 2024, with 72.14% growth.
Revenue
69.67M
Revenue Growth
-10.32%
P/S Ratio
5.87
Revenue / Employee
278.70K
Employees
250
Market Cap
408.76M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 22.67B |
Fresenius SE & Co. KGaA | 21.83B |
Bayer Aktiengesellschaft | 46.61B |
Sartorius Aktiengesellschaft | 3.44B |
Fresenius Medical Care AG | 19.34B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.26B |
Formycon AG News
- 21 days ago - EQS-AFR: Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements - Wallstreet:Online
- 5 weeks ago - Formycon's 2024: Financial Success & Market Growth - Wallstreet:Online
- 5 weeks ago - EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position - Wallstreet:Online
- 6 weeks ago - EQS-News: Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025 - Wallstreet:Online
- 2 months ago - EQS-News: FYB202/Otulfi (ustekinumab-aauz), a biosimilar to Stelara, launched in the United States and the European Union - Wallstreet:Online
- 2 months ago - EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea, under the brand name AHZANTIVE - Wallstreet:Online
- 2 months ago - EQS-DD: Formycon AG: Dr. Andreas Seidl, buy - Wallstreet:Online
- 2 months ago - EQS-News: Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin - Wallstreet:Online